Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients

被引：19
|
作者：
Kawai, Taketo [1 ]
Sato, Yusuke [1 ]
Makino, Katsuhiro [1 ]
Yamada, Yuta [1 ]
Nomiya, Akira [1 ]
Nakamura, Masaki [1 ]
Yamada, Daisuke [1 ]
Suzuki, Motofumi [1 ]
Igawa, Yasuhiko [1 ]
Kume, Haruki [1 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2019年 / 116卷
关键词：
ASSOCIATION; NIVOLUMAB;
D O I：
10.1016/j.ejca.2019.05.017
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：114 / 115
页数：2
相关论文
共 50 条
  • [41] Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
    Kurokawa, Kana
    Mitsuishi, Yoichiro
    Shimada, Naoko
    Kawakami, Yuta
    Miura, Keita
    Miyawaki, Taichi
    Asao, Tetsuhiko
    Ko, Ryo
    Shukuya, Takehito
    Shibayama, Rina
    Nojiri, Shuko
    Takahashi, Kazuhisa
    BMC CANCER, 2022, 22 (01)
  • [42] Associations between tumor response to pembrolizumab and immune-related adverse events in metastatic melanoma patients
    Geszti, F.
    Czirbesz, K.
    Kenessey, I.
    Liszkay, G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB24 - AB24
  • [43] Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
    Albarran-Artahona, Victor
    Laguna, Juan-Carlos
    Gorria, Teresa
    Torres-Jimenez, Javier
    Pascal, Mariona
    Mezquita, Laura
    DIAGNOSTICS, 2022, 12 (09)
  • [44] Cutaneous immune-related adverse events are undertreated in advanced cancer patients
    Chang, M.
    Otto, T.
    Jacoby, T.
    Thompson, L.
    Reynolds, K.
    Chen, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (09) : B10 - B10
  • [45] Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
    Shah, N.
    Jacob, J.
    Househ, Z.
    Shiner, E.
    Baird, L.
    Soudy, H.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [46] Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
    Noguchi, Susumu
    Suminaga, Keiichiro
    Kaki, Takahiro
    Kawachi, Hiroaki
    Fukao, Akari
    Terashita, Satoshi
    Horikawa, Sadao
    Ikeue, Tatsuyoshi
    Sugita, Takakazu
    LUNG CANCER-TARGETS AND THERAPY, 2020, 11 : 53 - 57
  • [47] Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis
    Ando, Takayuki
    Ueda, Akira
    Ogawa, Kohei
    Motoo, Iori
    Kajiura, Shinya
    Nakajima, Takahiko
    Hirano, Katsuhisa
    Okumura, Tomoyuki
    Tsukada, Kenichiro
    Hara, Takuo
    Suzuki, Nobuhiro
    Nakada, Naokatsu
    Horikawa, Naoki
    Fujii, Tsutomu
    Yasuda, Ichiro
    IN VIVO, 2021, 35 (01): : 475 - 482
  • [48] Immune-Related Adverse Events Due to Cancer Immunotherapy
    Benesova, Karolina
    Leipe, Jan
    AKTUELLE RHEUMATOLOGIE, 2020, 45 (06) : 535 - 543
  • [49] Testing Immune-Related Adverse Events in Cancer Immunotherapy
    Farmer, Jocelyn R.
    CLINICS IN LABORATORY MEDICINE, 2019, 39 (04) : 669 - +
  • [50] Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
    Liang, Yao
    Maeda, Osamu
    Ando, Yuichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, : 365 - 375
12345